Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘ECCO Amsterdam 2013’

Preview of key ALK lung cancer abstracts at ECCO 2013

Amsterdam: There’s a lot going on in lung cancer right now, which is pretty amazing when you consider only a couple of years ago we were still talking only chemotherapies and EGFR inhibitors.

Much of the new attention has been on the EML4-ALK translocation, the T790M mutation responsible for EGFR resistance as well as the possibility of improved survival with either MET or MEK inhibition. There are others, but these are the main ones that jump to mind.

Today, I want to focus on ALK+ lung cancer and what’s in store at ECCO at the weekend.

To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content. 

This content is restricted to subscribers

A top line look at the PD-1 and PD-L1 abstracts at ECCO 2013

Amsterdam: Check point immunotherapy is probably on everyone’s hot topic list in oncology at the moment and rightly so.

One of the key sessions I’m looking forward to at ECCO is the Saturday Lung Cancer Symposium on new therapeutic targets. It includes not only a presentation on PD-1 and PD-L1 Immune checkpoint antibodies, but also overviews of progress in several other pathways, namely PI3K-AKT-mTOR, RAS-RAF-MEK and ALK+/Hsp inhibitors. This should be an excellent session that allows a broad overview of many of the key areas of research in the disease.

Aside from a late breaker on the two-year ipilimumab data in metastatic melanoma, the check point abstracts I managed to find in the #ECC2013 program appear to be all posters.  Here are my quick notes ahead of the presentations for Premium Content subscribers:

To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content. 

This content is restricted to subscribers

error: Content is protected !!